Skip to main content

Lilly Endowment Inc's Form 4 filing

Eli Lilly & Co (LLY) · filed Aug 5, 2021

Accession no.
0001209191-21-049909
Filed
Aug 5, 2021
Trade date
Aug 4, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 10 non-derivative transactions. Open-market sales total $3.57M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lilly Endowment IncCIK 000031601110% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 4, 2021Common StockSSaleDisposed−369$260.19F1−$96,010.11108,525,189Direct
Aug 4, 2021Common StockSSaleDisposed−352$261.59F2−$92,079.68108,524,837Direct
Aug 4, 2021Common StockSSaleDisposed−1,214$262.74F3−$318,966.36108,523,623Direct
Aug 4, 2021Common StockSSaleDisposed−2,210$263.48F4−$582,290.8108,521,413Direct
Aug 4, 2021Common StockSSaleDisposed−2,410$264.53F5−$637,517.3108,519,003Direct
Aug 4, 2021Common StockSSaleDisposed−2,430$265.52F6−$645,213.6108,516,573Direct
Aug 4, 2021Common StockSSaleDisposed−2,409$266.70F7−$642,480.3108,514,164Direct
Aug 4, 2021Common StockSSaleDisposed−1,085$267.76F8−$290,519.6108,513,079Direct
Aug 4, 2021Common StockSSaleDisposed−679$268.54F9−$182,338.66108,512,400Direct
Aug 4, 2021Common StockSSaleDisposed−300$269.87F10−$80,961108,512,100Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.7119 to $260.59, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), and (10) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.0537 to $261.8898, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.06 to $263.05, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.06 to $264.0296, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.0783 to $265.0472, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.0931 to $266.0919, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.147 to $267.1199, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.1545 to $268.1217, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.1603 to $269.0285, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.2683 to $270.25, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)